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INTRODUCTION
Hyperglycemia can exacerbate a number of perioperative prob-
lems, including cardiac, neurologic, and infectious complications
(1). Strict perioperative glycemic control is effective for protecting
against injury in many organs and reducing the incidence of in-
fection, and is thus thought to lead to improved prognosis (2, 3).
Establishment of a new perioperative blood glucose control method
with the aid of an artificial endocrine pancreas (STG-22, Nikkiso
Co., Ltd., Tokyo, Japan) (Figure 1, left) was previously reported
(4-7). The purpose of this study was to assess the accuracy and
efficacy of the intraoperative application of a newly developed, next-
generation artificial endocrine pancreas (STG-55 ; Nikkiso Co.,
Ltd., Tokyo, Japan) (Figure 1, right).
METHODS
This investigation conformed to the principles outlined in the
Declaration of Helsinki. The study protocol was approved by the
Ethics Committee on Human Studies of Tokushima University Hos-
pital, and written informed consent was obtained from each patient.
Twenty patients scheduled to undergo surgery (four hepatectomies,
three liver transplantations, two pancreaticoduodenectomies, three
pancreas head-tailpiece resections, and eight cardiovascular sur-
geries without cardiopulmonary bypass : six cases of off -pump
coronary artery bypass grafting and two femoro-femoral artery
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Figure 1. The conventional artificial endocrine pancreas (left : STG-22,
Nikkiso Co., Ltd., Tokyo, Japan) and the newly developed next -gener-
ation artificial endocrine pancreas (right : STG-55, Nikkiso), a bedside-
type artificial endocrine pancreas with a closed- loop system.
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bypasses) were enrolled in this study. Diagnoses of the patients
were as follows : four hepatocellular carcinoma, two liver cirrhosis,
one fulminant hepatitis, five pancreatic cancer, six angina pectoris,
two arteriosclerosis obliterans). Patients’ characteristics were as
follows : age, 54-87 years ; height, 129.1-178.0 cm ; weight, 39.7 -
91.4 kg ; body mass index, 17.8-30.6 kg/m2 ; gender (male/fe-
male), 13/7 ; previous diabetes mellitus, 4 patients ; and metabolic
syndrome, 2 patients.
The newly developed artificial endocrine pancreas (STG-55) is
designed to be more user- friendly than its conventional counterpart
(STG-22) while maintaining the latter’s fundamental functions,
such as a closed- loop system using algorithms for insulin and
glucose infusion. The device is equipped with a disposable and
modular tubing circuit with an auto-priming function, a sensor set-
up with automatic calibration and quick response, and a compact
structure (Figure 2). It has been specifically modified to comply
with surgical and ICU needs (8, 9). Table 1 shows the differences
between STG-22 and STG-55. STG-55 has many new and bene-
ficial features.
Rapidlab860 (Bayer Medical, Tokyo, Japan) was used for con-
ventional blood glucose assessment. After anesthetic induction,
a 20G intravenous catheter was inserted into a peripheral fore-
arm vein and connected to the continuous blood glucose monitor.
A radial arterial catheter was also inserted to obtain samples for
blood glucose determination. The blood glucose determination was
carried out approximately once an hour for a stable condition. The
resultant 105 scores for paired blood glucose values obtained with
continuous glucose measurements (STG-55) and with conven-
tional intermittent glucose measurements (Rapidlab 860) were
compared.
The accuracy of continuous glucose measurements (STG-55)
and that of conventional intermittent glucose measurements
(Rapidlab 860) were compared by a Bland-Altman plot (10). In
addition, the values obtained using the two methods were sub-
jected to correlation analysis. StatView version 5.0 (SAS institute
Inc., Cary, NC) was used for the statistical analysis, and P0.05
was considered to be statistically significants.
RESULTS
Stable blood glucose values were maintained automatically,
and there were no complications related to use of the STG-55. A
close correlation (r=0.96) was observed between continuous glu-
cose measurements by the STG-55 and conventional intermittent
glucose measurements (Rapidlab 860) (Figure 3, left). Significant
agreement was also observed when the differences between the
two measurements were plotted against their mean values (Figure
3, right).
Figure 2. STG-55 (Nikkiso), equipped with a disposable and modu-
lar tubing circuit with an auto -priming function, automatic calibration
with quick response in the sensor set -up, and a compact structure.
Table 1 : Comparison between STG-22 and STG-55
Conventional artificial
pancreas, STG-22
Next -generation artificial
pancreas, STG-55
Size (mm) 505 (W)565 (D)1335 (H)
375 (W)425 (D)
1350 (H)
Weight (kg) 62 36
Preparation on
the previous day
Necessary for sensor
aging Not necessary
Battery Not installed Installed
Consumables Reusable partially Single use within 24hours
Priming function Not installed Installed
Data display/
output External printer/cable
Liquid crystal display/
USB
Time of prepara-
tion (hours) 3 -12 1-1.5
Figure 3. Accuracy of continuous blood glucose monitoring during surgery.
Left : Correlations between continuous glucose measurements (STG-55) and conventional intermittent glucose measurements (Rapidlab 860).
Right : Differences between the two measurements plotted against their mean (Bland-Altman plot of continuous glucose measurements (STG-55)
and conventional intermittent glucose measurements (Rapidlab 860)).
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The difficulty of manipulation using this system was decreased
by improved preparation procedures. In all patients, there was no
hypoglycemia during the perioperative period. Figure 4 shows a
typical example of intraoperative blood glucose changes (a 64-
year-old male patient undergoing pancreaticoduodenectomy).
Continuous monitoring and control of blood glucose were suc-
cessfully attained with the aid of the artificial endocrine pancreas
(STG-55). A suitable blood glucose level was ensured by appro-
priate insulin administration.
DISCUSSION
Hyperglycemia induced by surgical stress often causes dys-
regulation of liver metabolism and immune function, resulting in
impaired post-operative recovery. Several mechanisms have been
proposed to explain the adverse effects of hyperglycemia. It was
found that persistent hyperglycemia resulted in functional decline
of neutrophils. Infection is thus the critical problem resulting from
hyperglycemia in the acute phase of the post-operative period.
Additionally, hyperglycemia can exacerbate a number of periopera-
tive problems, including cardiac and neurologic complications (1).
On the other hand, hypoglycemia may also cause severe neu-
rologic complications dependent on its duration and absolute value
of plasma glucose. Furthermore, recent studies have shown that
reducing the variability of blood glucose concentration may play
an important role in glucose management (11). Anesthesiologists
must avoid severe hypo- or hyperglycemia during surgery.
However, it has also been shown that intensive insulin treat-
ment is sometimes difficult to perform when using sliding-scale
manual insulin injection because hypo/hyperglycemia often occurs
in spite of frequent blood glucose testing. It has therefore been
suggested that continuous blood glucose monitoring would be
beneficial for maintaining target blood glucose levels.
The usefulness of a closed- loop system (artificial endocrine
pancreas) to achieve strict glycemic control during surgery was
reported (12-14). The artificial endocrine pancreas (STG-22) pro-
vides continuous blood glucose monitoring through a dual lumen
catheter blood sampling technique, a high-quality roller pump
(multichannel pump), and a glucose sensor electrode with a glu-
cose oxidase membrane. Before starting blood glucose monitoring,
two-point calibration was performed using a standard solution
for internal calibration (glucose concentration : 0 mg/dl) and a
standard glucose solution (200 mg/dl). During blood glucose
monitoring, internal calibration using the standard solution for
internal calibration was performed automatically every 4 h. After
calibration of the equipment, blood was sampled continuously from
a peripheral vein at a rate of 2 ml/h and continuously diluted with
a heparinized isotonic solution. The diluted blood was further
diluted with an isotonic buffer solution of phosphoric acid, pH
7.4, after which the glucose sensor electrode was exposed to the
sampled blood. The multichannel pump and the glucose sensor
electrode both had an accuracy of5%. The accuracy and reli-
ability of this system during and after surgery have been confirmed
(15, 16). In this study, the results using STG-55 were similar to
those obtained with the conventional artificial pancreas (STG-22).
In December 2007, our clinical team at Tokushima University
Hospital initiated a clinical trial to evaluate the efficacy of the ar-
tificial pancreas for intra-operative patients. Two Nikkiso STG-22
artificial pancreas systems were put into clinical use at Tokushima
University Hospital for intra- and post-operative glucose control.
The usefulness of a closed- loop system providing continuous moni-
toring and strict control of perioperative blood glucose in patients
during several surgeries was also reported (4-7).
However, improved preparation procedures are needed to re-
duce the difficulty of manipulation using this system. Such a new
device has to be simple to use and easily adaptable to various clini-
cal situations, including emergency medicine. This newly developed
artificial pancreas was approved by the Ministry of Health, Labour
and Welfare of Japan in late 2009. This next-generation artificial
endocrine pancreas, equipped with a disposable and modular tub-
ing circuit with an auto-priming function, automatic calibration
with quick response in sensor set-up, and a compact structure,
is also available (8, 9). The most beneficial point seems to be the
improved glucose sensor. This glucose sensor is newly developed
for single use in order to avoid long preparation. It is now com-
pact and can reduce the preparation time, including the perform-
ance of sensor aging and the assembly of disposable tubing parts.
The conventional artificial pancreas (STG-22) requires 3-12 hours
of operation before starting the glucose sensor, so it should ideally
be started the day before surgery. In contrast, the new sensor in
the STG-55 only requires 5 minutes of warm-up before use.
In December 2011, the next-generation model of this artificial
endocrine pancreas, the STG-55 (Nikkiso), was put into clinical
use at our hospital. We are using this device for patients with un-
stable intraoperative blood glucose control, including diabetic pa-
tients and those with insulinoma, or those who had undergone a
total pancreatectomy or liver transplantation, hepatectomy, or car-
diovascular surgery. The blood glucose levels of these patients
fluctuated significantly during surgery, and were very difficult to
control when using intermittent glucose measurements and manual
insulin injections. By using this device, stable blood glucose values
were maintained automatically (Figure 4), and there were no com-
plications related to the use of this device.
In conclusion, we believe that it is necessary to establish a strict
glycemic control strategy because, in view of the global increase
in diabetes, it is expected that good glycemic control in surgical
and emergency settings will become more and more important.
Artificial endocrine pancreas (STG-55) could be a powerful tool to
achieve safe and strict glycemic control by accurate and continu-
ous blood glucose monitoring, and closed- loop glycemic control
systems. Establishment of a new perioperative blood glucose con-
trol method with the aid of an artificial endocrine pancreas is ur-
gently needed.
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Figure 4. Glycemic control in a typical case using artificial endocrine
pancreas (a 64-year -old male patient during pancreaticoduodenectomy).
The target glucose level range was set at 80 -150 mg/dl. The insulin in-
fusion rate increased according to the increase in glucose concentration.
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